MedTrace Logo

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

NCT00091598 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 372

Last updated 2010-03-08

No results posted yet for this study

Summary

The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Ambrisentan

Sponsors & Collaborators

Principal Investigators

  • Lewis J. Rubin, MD · University of California San Diego, San Diego School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2006-02-28
Completion
2006-02-28

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00091598 on ClinicalTrials.gov